BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 31293046)

  • 21. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.
    Beijers AJ; Oerlemans S; Mols F; Eurelings M; Minnema MC; Vreugdenhil A; van de Poll-Franse LV
    Ann Hematol; 2017 Apr; 96(4):653-663. PubMed ID: 28116479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.
    Sreeram K; Seaton R; Greenwald MK; Kamgar M; Assad H; Baird T; Schwartz AG; Ruterbusch J; Simon MS
    Cancer Causes Control; 2023 May; 34(5):459-468. PubMed ID: 36934365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.
    Kanda K; Fujimoto K; Mochizuki R; Ishida K; Lee B
    BMC Cancer; 2019 Sep; 19(1):904. PubMed ID: 31506070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study.
    Hsu HT; Wu LM; Lin PC; Juan CH; Huang YY; Chou PL; Chen JL
    Medicine (Baltimore); 2020 Feb; 99(6):e19029. PubMed ID: 32028414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mindfulness is associated with severity of peripheral neuropathy and related patient-reported outcomes among colorectal cancer patients.
    Bonhof CS; van de Poll-Franse LV; de Hingh IH; Vreugdenhil G; Mols F
    Support Care Cancer; 2022 Nov; 30(11):9517-9526. PubMed ID: 36030458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
    Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. It's never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial.
    Kneis S; Wehrle A; Müller J; Maurer C; Ihorst G; Gollhofer A; Bertz H
    BMC Cancer; 2019 May; 19(1):414. PubMed ID: 31046719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy.
    Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB
    Gait Posture; 2021 Sep; 89():178-185. PubMed ID: 34320441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symptoms of anxiety but not depression before start of taxane-based chemotherapy are associated with peripheral neuropathy: a multicenter study in women with breast cancer.
    Verhoeff-Jahja R; Ter Kuile MM; Weijl NI; Oosterkamp R; Cloos M; Portielje JEA; Kroep JR; Hinnen C
    Support Care Cancer; 2022 Aug; 30(8):6947-6953. PubMed ID: 35543818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
    Knoerl R; Weller E; Halpenny B; Berry D
    BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.
    Bulls HW; Hoogland AI; Kennedy B; James BW; Arboleda BL; Apte S; Chon HS; Small BJ; Gonzalez BD; Jim HSL
    Gynecol Oncol; 2019 Feb; 152(2):310-315. PubMed ID: 30558975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
    Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
    Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired Postural Control and Altered Sensory Organization During Quiet Stance Following Neurotoxic Chemotherapy: A Preliminary Study.
    Monfort SM; Pan X; Loprinzi CL; Lustberg MB; Chaudhari AMW
    Integr Cancer Ther; 2019; 18():1534735419828823. PubMed ID: 30741022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
    Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
    Winters-Stone KM; Krasnow SM; Horak FB; Mancini M; Cameron MH; Dieckmann NF; Stoyles SA; Roeland EJ
    BMC Cancer; 2023 Nov; 23(1):1087. PubMed ID: 37946117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
    Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
    Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.
    McCrary JM; Goldstein D; Wyld D; Henderson R; Lewis CR; Park SB
    J Cancer Surviv; 2019 Aug; 13(4):495-502. PubMed ID: 31172429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
    Alberti P; Rossi E; Cornblath DR; Merkies IS; Postma TJ; Frigeni B; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; Cavaletti G;
    Ann Oncol; 2014 Jan; 25(1):257-64. PubMed ID: 24256846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors.
    Teng C; ; Blinman PL; Vardy JL
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1308-1315. PubMed ID: 36509075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.